What’s the Deal with Generex Biotechnology Corporation (OTCMKTS:GNBT)?

What’s the Deal with Generex Biotechnology Corporation (OTCMKTS:GNBT)?


One stock that’s suddenly back on the map is Generex Biotechnology Corporation (OTCMKTS:GNBT). Helping to foster the stock’s massive move to close out last week was the company’s announcement that it has completed the second and final tranche of the acquisition of operating assets from Veneto Holdings, L.L.C., a private company, and certain of its affiliated entities.

According to the release, “The Veneto Group provides specialty pharmacy services and products including surgical products and services, diagnostic testing for screening human blood, urine and/or saliva samples for the presence of narcotics, medications, alcohol and other drugs and substances, durable medical equipment services, and ancillary healthcare services such as management services for its businesses.”

Generex Biotechnology Corporation (OTCMKTS:GNBT) trumpets itself as a company engaged in the research, development, and commercialization of drug delivery systems and technologies.

As the company states, Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company’s proprietary RapidMist device. Antigen Express, Inc. is a wholly owned subsidiary of Generex.

The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells.

According to company materials, “Hema Diagnostic Systems, LLC (www.rapid123.com) is a rapidly growing biotechnology company involved in the development, manufacture, assembly, and distribution of diagnostics targeting primary as well as orphan infectious diseases. Hema Diagnostic Systems continues to expand its product line to meet the needs of the worldwide market. Point-of-Care test devices are made simple to use and are highly cost effective when incorporated into Hema Diagnostic Systems’ patented and patent pending delivery systems. The Rapid 1-2-3 Hema EXPRESS is a novel delivery system that is self-contained and easy to use.”

Find out when $GNBT reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

As noted above, GNBT just announced that it has completed the second and final tranche of the acquisition of operating assets from Veneto Holdings, L.L.C., a private company, and certain of its affiliated entities.

We’ve witnessed just under 510% added to share values of the company over the past month of action. What’s more, the stock has registered increased average transaction volume recently, with the past month seeing a bit less than 630% above the average volume levels in play in this stock over the longer term. This is particularly important given the stock’s very limited trading float of 670K shares.

Commenting on this important milestone for Generex, Joseph Moscato, President & Chief Executive Officer, commented, “The completion of this acquisition provides us with revenue generating assets and brings us one step closer to realizing our vision of building a new kind of pharmaceutical company that provides end-to-end solutions for doctors and patients optimizing health outcomes. Generex is now able to provide administration and management services to pharmacies, labs, and other ancillary networks that enable them to deliver better patient care. These services are complemented by a centralized call-center that provides medication therapy and disease management services. So far, this model is implemented in five states (Arizona, Colorado, New Mexico, Oklahoma, and Texas). However, our expansion plan is already underway to implement the model in 22 states where we expect to have operations by the end of 2020.”

Earning a current market cap value of $22.9M, GNBT has a reserve ($1M) of cash on the books, which compares with about $25.2M in total current liabilities. GNBT is pulling in trailing 12-month revenues of $703K. However, the company is seeing recent declines on the top-line on a sequential quarterly basis, with revenues falling at 0% as of its latest reporting period. As more color becomes clear on the name, we will review the situation and update our take. Sign-up for continuing coverage on shares of $GNBT stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $GNBT, either long or short, and we have not been compensated for this article.

Sign Up for our 100% FREE Oracle Dispatch Newsletter